KUSHEN宁胶置入对宫颈癌三维近距离放疗直肠壁剂量体积效应的影响
该前瞻性研究评估了宫颈癌患者近距离放疗(600 cGy)中置入KUSHEN宁胶前后直肠壁的剂量体积变化,比较了全直肠壁、前壁和后壁的空间剂量分布。结果显示置入后全直肠壁体积增加,全直肠壁和前壁D2cc均值升高,而后壁D2cc均值降低(P<0.05),后壁高剂量照射相对体积减少。结论认为置入KUSHEN宁胶可保护直肠,安全性良好。
要点
- 置入KUSHEN宁胶后全直肠壁体积增加,前壁D2cc均值升高而后壁D2cc均值降低。
- 置入后后壁高剂量照射相对体积减少,提示对后壁的保护作用。
- 回归分析显示DR-p-max与VR-w和D2ccR-p相关性最强(P<0.01和P<0.05)。
核心结论
- 置入KUSHEN宁胶可保护直肠,安全性良好且耐受性佳,可能减少近距离放疗后的不良事件。
研究设计与样本
- 将全直肠壁分为前壁和后壁,构建全直肠壁剂量表面图并比较各壁体积。
主要发现
- 置入后全直肠壁体积较置入前增加。
- 置入后全直肠壁和前壁D2cc均值分别从532.45 cGy升至564.7 cGy、从533.51 cGy升至565.26 cGy。
- 置入后后壁D2cc均值从260.5 cGy降至240.0868 cGy(P<0.05)。
- 置入后后壁高剂量照射相对体积减少。
- 回归分析显示DR-p-max与VR-w和D2ccR-p相关性最强(P<0.01和P<0.05)。
关键数值与推荐
- 近距离放疗处方剂量为600 cGy。
- 置入后全直肠壁D2cc均值564.7 cGy,前壁565.26 cGy,后壁240.0868 cGy。
- 置入前后壁D2cc均值为260.5 cGy。
临床怎么用
- 宫颈癌三维近距离放疗中可考虑置入KUSHEN宁胶以降低后壁高剂量照射体积。
- 置入后需关注前壁D2cc均值升高,个体化评估直肠壁剂量分布。
局限性
- 试验为回顾性注册(ChiCTR1900021631,2019年3月2日)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The present prospective study evaluated the safety and efficacy of the rectum following KUSHEN Ningjiaos in cervical cancer. We compared rectal wall changes during brachytherapy with or without KUSHEN Ningjiaos in cervical cancer patients and analyzed the difference in spatial dose distribution, including whole rectum-wall (R-w), anterior rectum-wall (R-a) and posterior rectum-wall (R-p). METHODS AND MATERIALS: One hundred cervical cancer patients with and without KUSHEN Ningjiaos were treated with brachytherapy (600 cGy). The whole R-w was divided into two areas of R-a and R-p, and R-w dose surface map were constructed. The volume of each R-w was compared in patients pre- and post-KUSHEN Ningjiaos. RESULTS: When the pre- vs. post-KUSHEN groups were compared the volume of R-w increased. In the post-KUSHEN group, a significantly higher proportion of the D2cc of VR-w and VR-a compared with the pre-KUSHEN group showed that the D2ccmean increased from 532.45 cGy to 564.7 cGy and 533.51 cGy to 565.26 cGy, respectively; however, results demonstrated a decrease in the D2ccmean of R-p from 260.5 cGy to 240.0868 cGy (P < 0.05). The insertion of KUSHEN Ningjiaos resulted in a reduction of the relative volume of R-p exposed to high doses, and regressive analysis showed that the DR-p-max correlated most strongly with VR-w and D2ccR-p (P < 0.01 and P < 0.05, respectively). CONCLUSION: The insertion of KUSHEN Ningjiaos can protect the rectum. KUSHEN Ningjiaos appears to be safe and well tolerated; therefore, we believe that there will be fewer adverse events after brachytherapy for patients. TRIAL REGISTRATION: A multi-center, prospective clinical trial for KUSHEN Ningjiaos was inserted into rectum to reduce the rate of radiation proctitis in three-dimensional brachytherapy of cervical cancer. ChiCTR1900021631 . 2 Mar 2019-Retrospectively registered.
引用
- Li X, Xiao C, Kong Y, et al. Rectal wall dose-volume effect of pre- or post KUSHEN Ningjiaos relationship with 3D brachytherapy in cervical cancer patients. Radiat Oncol. 2019. PMID: 31429773. doi:10.1186/s13014-019-1354-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。